logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Sumitomo Pharma Oncology, Inc.


USPTO Granted Patents = 11



Forward Citations = 14

Loading Chart...
Loading Chart...

30 inventors (with patents filed for the assignee):

goldMedal Adam Siddiqui-Jain (8 out of 25 patents)

silverMedal Steven L Warner (6 out of 36 patents)

bronzeMedal David J Bearss (6 out of 50 patents)

4.  Paul Flynn (4 out of 7 patents)

5.  Jason Marc Foulks (2 out of 7 patents)

6.  Hirotaka Kurebayashi (2 out of 8 patents)

7.  Takahiko Hashizuka (2 out of 4 patents)

8.  Clifford J Whatcott (2 out of 9 patents)

9.  Yuka Arikawa (2 out of 4 patents)

10.  Shuji Masumoto (2 out of 8 patents)

11.  Hiroaki Tanaka (2 out of 38 patents)

12.  Hitoshi Ban (1 out of 41 patents)

13.  Seiji Kamioka (1 out of 18 patents)

14.  Yusuke Sawayama (1 out of 7 patents)

15.  Chiang Jia Li (1 out of 57 patents)


11 patents:

1. 12338261 - Alvocidib prodrugs having increased bioavailability (2025-06-24),
2. 12077554 - CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer (2024-09-03),
3. 11793802 - Treatment of acute myeloid leukemia (AML) with venetoclax failure (2023-10-24),
4. 11746103 - ALK-5 inhibitors and uses thereof (2023-09-05),
5. 11712433 - Compositions comprising PKM2 modulators and methods of treatment using the same (2023-08-01),
6. 11530231 - CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer (2022-12-20),
7. 11529350 - Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof (2022-12-20),
8. 11497756 - Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib (2022-11-15),
9. 11471456 - Formulations comprising heterocyclic protein kinase inhibitors (2022-10-18),
10. 11414394 - Process for producing a hydrate of a hydrochloride salt of 2,2'-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid (2022-08-16),
11. 11400091 - AXL kinase inhibitors and use of the same (2022-08-02),
Company Overview
Sumitomo Pharma Oncology, Inc., based in Cambridge, MA, focuses on the development of innovative therapies for cancer treatment. The company specializes in oncology research, leveraging advanced technologies to create targeted therapies that address unmet medical needs in oncology. With a commitment to improving patient outcomes, Sumitomo Pharma Oncology collaborates with various stakeholders in the healthcare ecosystem to advance its pipeline of therapeutic candidates and enhance the quality of life for cancer patients.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

11 Patents

#216 in Cambridge, MA

#1,661 in Massachusetts

#27,514 in US

#51,761 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Sumitomo Pharma Oncology, Inc.

Forward Citations = 14

30 inventors:

goldMedal Adam Siddiqui-Jain (8 out of 25 patents)

silverMedal Steven L Warner (6 out of 36 patents)

bronzeMedal David J Bearss (6 out of 50 patents)

4.  Paul Flynn (4 out of 7 patents)

5.  Jason Marc Foulks (2 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Sumitomo Pharma Oncology, Inc.. Retrieved from https://idiyas.com/company/sumitomo-pharma-oncology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…